2-氟-3-异丙氧基苯硼酸 | 855230-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氟-3-异丙氧基苯硼酸
• 英文名称: 2-fluoro-3-isopropoxyphenylboronic acid
• 英文别名: [2-fluoro-3-(propan-2-yloxy)phenyl]boronic acid；(2-fluoro-3-propan-2-yloxyphenyl)boronic acid
• CAS: 855230-63-6
• 化学式: C₉H₁₂BFO₃
• mdl: MFCD11504844
• 分子量: 198.002
• InChiKey: CHXPLNUWFRHWDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.28
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-3-isopropoxyphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-3-isopropoxyphenylboronic acid
CAS number: 855230-63-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12BFO3
Molecular weight: 198.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-3-异丙氧基苯硼酸 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 水 、 叔丁醇 为溶剂， 反应 9.0h， 生成 N-(3,4-dimethylisoxazol-5-yl)-4-{[4-(2-fluoro-3-isopropoxyphenyl)pyrimidin-2-yl]amino}benzenesulfonamide
  参考文献：
  名称：

  Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

  摘要：

  Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226). (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.01.002

文献信息

• [EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017060854A1

  公开（公告）日：2017-04-13

  The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。
• [EN] PYRIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] DÉRIVÉS DE PYRIDINONE ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011076687A1

  公开（公告）日：2011-06-30

  Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related conditions in both men and women, as well as a mammal in general (also referred to herein as a "subject"). For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, heavy menstrual bleeding, particularly menorrahagia and dysmenorrehea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to pyridinone derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  吡啶酮衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于制造用于治疗和/或预防疾病的药物的用途，特别是用于男性和女性的性激素相关疾病，以及一般哺乳动物（在本文中也称为“受试者”）。例如，这些疾病包括子宫内膜异位症、子宫肌瘤、多囊卵巢综合征、月经过多出血，尤其是月经过多和月经痛、多毛症、早熟、依赖性生殖腺类固醇的肿瘤，如前列腺、乳腺和卵巢癌、性腺激素释放激素依赖性垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕（例如，辅助生殖疗法，如体外受精）。本申请特别涉及吡啶酮衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂。
• 1H-imidazo[4,5-c]quinolinone derivatives
  申请人：Furet Pascal

  公开号：US08476294B2

  公开（公告）日：2013-07-02

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐治疗蛋白质和/或脂质激酶依赖性疾病，以及用于制造治疗该等疾病的药物制剂；1H-咪唑[4,5-c]喹啉酮衍生物用于治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗上述疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包含1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新颖的1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新颖的1H-咪唑[4,5-c]喹啉酮衍生物的方法。
• 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES
  申请人：Furet Pascal

  公开号：US20140005163A1

  公开（公告）日：2014-01-02

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐治疗蛋白质和/或脂质激酶依赖性疾病，并用于制备治疗该类疾病的药物制剂；使用1H-咪唑[4,5-c]喹啉酮衍生物治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗该类疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包含1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新型1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新型1H-咪唑[4,5-c]喹啉酮衍生物的方法。
• 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
  申请人：FURET Pascal

  公开号：US20100317657A1

  公开（公告）日：2010-12-16

  The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone derivatives.

  本发明涉及使用1H-咪唑[4,5-c]喹啉酮衍生物及其盐在治疗蛋白质和/或脂质激酶依赖性疾病和制造治疗该类疾病的药物制剂；1H-咪唑[4,5-c]喹啉酮衍生物用于治疗蛋白质和/或脂质激酶依赖性疾病；一种治疗上述疾病的方法，包括向温血动物，特别是人类，给予1H-咪唑[4,5-c]喹啉酮衍生物；包括1H-咪唑[4,5-c]喹啉酮衍生物的药物制剂，特别用于治疗蛋白质和/或脂质激酶依赖性疾病；新型1H-咪唑[4,5-c]喹啉酮衍生物；以及制备新型1H-咪唑[4,5-c]喹啉酮衍生物的方法。